Free Trial
OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Chugai Pharmaceutical logo
$26.53 +0.22 (+0.84%)
As of 05/27/2025 04:00 PM Eastern

About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY)

Key Stats

Today's Range
$26.04
$27.45
50-Day Range
$21.89
$30.18
52-Week Range
$14.52
$31.26
Volume
103,480 shs
Average Volume
198,412 shs
Market Capitalization
$87.31 billion
P/E Ratio
34.45
Dividend Yield
0.94%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Chugai Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

CHGCY MarketRank™: 

Chugai Pharmaceutical scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Chugai Pharmaceutical.

  • Earnings Growth

    Earnings for Chugai Pharmaceutical are expected to grow by 5.41% in the coming year, from $0.74 to $0.78 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chugai Pharmaceutical is 34.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.87.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chugai Pharmaceutical is 34.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.92.

  • Price to Book Value per Share Ratio

    Chugai Pharmaceutical has a P/B Ratio of 6.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Chugai Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Chugai Pharmaceutical have been sold short.
  • Short Interest Ratio / Days to Cover

    Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chugai Pharmaceutical has recently decreased by 32.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Chugai Pharmaceutical pays a meaningful dividend of 1.01%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Chugai Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Chugai Pharmaceutical is 30.86%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 32.05% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Chugai Pharmaceutical's dividend.
  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Chugai Pharmaceutical have been sold short.
  • Short Interest Ratio / Days to Cover

    Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chugai Pharmaceutical has recently decreased by 32.32%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Chugai Pharmaceutical this week, compared to 0 articles on an average week.
Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

CHGCY Stock News Headlines

Chugai Pharmaceutical Co., Ltd. (4519.T)
Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
Jefferies Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)
Bernstein Remains a Buy on Chugai Pharmaceutical Co (CHGCF)
See More Headlines

CHGCY Stock Analysis - Frequently Asked Questions

Chugai Pharmaceutical's stock was trading at $21.97 at the start of the year. Since then, CHGCY shares have increased by 20.8% and is now trading at $26.53.
View the best growth stocks for 2025 here
.

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) posted its earnings results on Thursday, April, 24th. The company reported $0.19 EPS for the quarter. The firm had revenue of $1.89 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a trailing twelve-month return on equity of 21.53%.

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/24/2025
Today
5/28/2025
Next Earnings (Estimated)
7/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
N/A
Current Symbol
OTCMKTS:CHGCY
Fax
N/A
Employees
7,604
Year Founded
N/A

Profitability

Trailing P/E Ratio
34.45
Forward P/E Ratio
35.85
P/E Growth
N/A
Net Income
$2.56 billion
Pretax Margin
46.39%

Debt

Sales & Book Value

Annual Sales
$7.74 billion
Cash Flow
$0.91 per share
Price / Cash Flow
29.01
Book Value
$3.81 per share
Price / Book
6.96

Miscellaneous

Outstanding Shares
3,291,028,000
Free Float
N/A
Market Cap
$87.31 billion
Optionable
Not Optionable
Beta
0.76
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:CHGCY) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners